Prophylactic and/or therapeutic administration of an NK1R antagonist (SR 14333, RP 67580, CP 96345, CP 99,994, SR 140333, or L 703,606) significantly reduced the severity of a number of experimental AP models (Grady et al., 2000; He et al., 2003; Lau et al., 2005; Lau and Bhatia, 2006; Sun and Bhatia, 2007; Camargo et al., 2008; Ramnath et al., 2009; Barreto et al., 2010; Li et al., 2018) and affected nociceptive behavior (Vera-Portocarrero and Westlund, 2004). Here, TACR1 is linked to alkaline phosphatase measurement.